GUANIDINE CARBONATE

US Previously Marketed

First approved in 1939

Details

Stereochemistry	ACHIRAL
Molecular Formula	2CH5N3.CH2O3
Molecular Weight	180.1659
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(=N)(N)N.C(=N)(N)N.C(=O)(O)O

InChI

InChIKey=STIAPHVBRDNOAJ-UHFFFAOYSA-N

InChI=1S/2CH5N3.CH2O3/c3*2-1(3)4/h2*(H5,2,3,4);(H2,2,3,4)

HIDE SMILES / InChI

Molecular Formula	CH2O3
Molecular Weight	62.0248
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH5N3
Molecular Weight	59.0705
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated potassium channel 14 Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21926190	Inhibitor 7728

Conditions

Condition	Modality	Targets	Highest Phase	Product
Eaton-Lambert syndrome 4 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	Palliative		Approved 8043	GUANIDINE HYDROCHLORIDE Approved Use Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date -9.5463362E11

PubMed

Title	Date	PubMed
Topological diversity of artificial beta-barrels in water.	2001	11270328
Expression and refolding of full-length human TIMP-1.	2001	11217305
Evolution and physiological roles of phosphagen systems.	2001	11181958
Strain-specified relative conformational stability of the scrapie prion protein.	2001 Apr	11274476
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin.	2001 Apr	11259312
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.	2001 Apr 12	11312922
Structure--function relationships in bovine thymus 20S proteasome: a fluorimetric study.	2001 Apr 12	11311722
Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site.	2001 Apr 24	11305927
Probing copper ligands in denatured Pseudomonas aeruginosa azurin: unfolding His117Gly and His46Gly mutants.	2001 Feb	11293412
Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes.	2001 Feb	11276368
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions].	2001 Feb	11218725
Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients.	2001 Feb	11168992
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.	2001 Feb	11168991
Uremic concentrations of guanidino compounds inhibit neutrophil superoxide production.	2001 Feb	11168990
Endogenous guanidino compounds as uremic neurotoxins.	2001 Feb	11168988
Specific neosaxitoxin interactions with the Na+ channel outer vestibule determined by mutant cycle analysis.	2001 Feb	11159437
Apparent two-state tendamistat folding is a sequential process along a defined route.	2001 Feb 16	11237606
Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells.	2001 Feb 16	11178976
The folding nucleus of a fibronectin type III domain is composed of core residues of the immunoglobulin-like fold.	2001 Feb 2	11162123
Rate of intrachain contact formation in an unfolded protein: temperature and denaturant effects.	2001 Feb 2	11162121
Uracil moiety is required for toxicity of the cyanobacterial hepatotoxin cylindrospermopsin.	2001 Feb 23	11245397
Efficient gene transfection by bisguanylated diacetylene lipid formulations.	2001 Feb 23	11181080
Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry.	2001 Jan	11180644
Dichlorobis(glycocyamine-O)copper(II).	2001 Jan	11173378
Phaeochromocytoma: an unusual cause of hypertension in pregnancy.	2001 Jan	11167434
Detection of enterovirus and hepatitis A virus RNA in mussels (Mytilus spp.) by reverse transcriptase-polymerase chain reaction.	2001 Jan	11155127
Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates.	2001 Jan 1	11169615
Limited tryptic hydrolysis of pea legumin: molecular mass and conformational stability of legumin-T.	2001 Jan 10	11164235
The influence of ATP on the association and unfolding of the tyrosine repressor ligand response domain of Haemophilus influenzae.	2001 Jan 12	11162481
Surprisingly high stability of barley lipid transfer protein, LTP1, towards denaturant, heat and proteases.	2001 Jan 19	11163761
Achieving stability and conformational specificity in designed proteins via binary patterning.	2001 Jan 19	11152617
A kinetic folding intermediate probed by native state hydrogen exchange.	2001 Jan 19	11152615
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.	2001 Jan 23	11170394
[Y97V substitution in the horse cytochrome c causes accumulation of the equilibrium intermediate].	2001 Jan-Feb	11236561
[Antibody avidity: use for the diagnosis of HIV early infection].	2001 Jan-Feb	11174099
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores.	2001 Jan-Feb	11148071
Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP.	2001 Mar	11315562
Structure-activity relationship of the p55 TNF receptor death domain and its lymphoproliferation mutants.	2001 Mar	11231290
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release.	2001 Mar	11222743
Cutinase unfolding and stabilization by trehalose and mannosylglycerate.	2001 Mar 1	11170208
Major differences in stability and dimerization properties of two chimeric mutants of human stefins.	2001 Mar 1	11170205
The synthesis of beta-peptides containing guanidino groups.	2001 Mar 12	11266170
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.	2001 Mar 15	11238669
Matrix proteins from insect pliable cuticles: are they flexible and easily deformed?	2001 Mar 15	11222954
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride.	2001 Mar 20	11258961
Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants.	2001 Mar 23	11263966
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states.	2001 Mar 30	11273710
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.	2001 Mar 30	11266439
Proton and metal ion-dependent assembly of a model diiron protein.	2001 May	11316876
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.	2001 May 15	11322922

Patents

Sample Use Guides

In Vivo Use Guide

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.

Route of Administration: Oral

In Vitro Use Guide

Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.

Substance Class	Chemical Created by `admin` on `Sat Jun 26 03:05:50 UTC 2021` Edited by `admin` on `Sat Jun 26 03:05:50 UTC 2021`
Record UNII	V3394X3G2W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GUANIDINE CARBONATE

Official Name

English

NSC-2171

Code

English

GUANIDINE CARBONATE [INCI]

Common Name

English

CARBONIC ACID, COMPD. WITH GUANIDINE (1:2)

Common Name

English

DIGUANIDINIUM CARBONATE

Systematic Name

English

GUANIDINE CARBONATE (2:1)

Systematic Name

English

BISGUANIDINIUM CARBONATE

Systematic Name

English

GUANIDINIUM CARBONATE

Systematic Name

English

Code System Code Type Description

ECHA (EC/EINECS)

209-813-7